[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Damascus Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":69},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100637972","phase-4-vonoprazan-high-dose-dual-vs-levofloxacin-concomitant-100637972",false,"NCT07624422","Vonoprazan High-Dose Dual VS Levofloxacin Concomitant","Efficacy and Safety of Vonoprazan High-Dose Dual Therapy Compared to Levofloxacin Concomitant Therapy for H. Pylori Eradication: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and ≤ 80 years (adjust upper limit as needed)\n* Confirmed Helicobacter pylori infection by at least one of the following: positive urea breath test, rapid urease test, histopathology, or stool antigen test\n* Treatment-naïve for H. pylori (no prior eradication therapy) - OR - prior treatment failure (specify if rescue therapy)\n* Willing and able to provide written informed consent\n* Willing to adhere to the 14-day treatment regimen and follow-up visits\n* For women of childbearing potential: negative pregnancy test and agreement to use effective contraception during the treatment period\n\nExclusion Criteria:\n\n* History of allergy or hypersensitivity to vonoprazan, amoxicillin, clarithromycin, metronidazole, or any other penicillin\u002Fcephalosporin\n* Previous H. pylori eradication therapy (if study is for first-line treatment)\n* Active gastrointestinal bleeding or perforation\n* Severe liver disease (Child-Pugh class B or C) or severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnancy or breastfeeding\n* Concurrent use of medications with significant drug-drug interactions (e.g., warfarin, phenytoin, digoxin, atazanavir, rilpivirine)\n* Malignancy or any life-threatening condition with life expectancy \\\u003C 6 months\n* Participation in another interventional trial within 30 days prior to enrollment\n* Any condition that, in the investigator's opinion, precludes safe participation or adherence to the protocol","ALL","18 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This is a randomized controlled trial comparing the efficacy and safety of two vonoprazan-based regimens: high-dose dual therapy (vonoprazan plus a single antibiotic) versus triple therapy (vonoprazan plus two antibiotics) for the treatment of H. pylori infection).\n\nParticipants will be randomly assigned to receive either regimen for 14 days. The primary outcome is eradication rate , and secondary outcomes include adverse events and treatment adherence.",[27,28,29],"Helicobacter Pylori Infection","Peptic Ulcer Disease","Gastritis",[27,31],"Vonoprazan","NOT_YET_RECRUITING","2026-06-01",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":21},"2026-11-01",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Damascus Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100521105","phase-4-levofloxacin-concomitant-versus-levofloxacin-sequential-100521105","NCT06065267","Levofloxacin Concomitant Versus Levofloxacin Sequential","Efficacy of Two-week Therapy With Levofloxacin-based Concomitant Regimen Versus Levofloxacin-based Sequential Regimen for Helicobacter Pylori Infection in Syrian Population: a Prospective Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients are aged greater than 18 years old who have H. pylori infection diagnosed by any of following three methods:\n* Positive rapid urease test (CLOtest).\n* Histologic evidence of H. pylori by modified Giemsa staining.\n* Positive 13C-urea breath test. without prior eradication therapy and are willing to receive therapy.\n\nExclusion Criteria:\n\n* Children and teenagers aged less than 18 years.\n* Previous eradication treatment for H. pylori.\n* Patients who took any drug, which could influence the study results such as proton pump inhibitor, H2 blocker, mucosal protective agent and antibiotics.\n* History of gastrectomy.\n* Gastric malignancy, including adenocarcinoma and lymphoma,\n* Previous allergic reaction to antibiotics (Amoxicillin, Tinadizole,\n* Doxycycline,Bismuth subsalicylate,) and prompt pump inhibitors (Es- omeprazole).\n* Contraindication to treatment drugs.\n* Pregnant or lactating women.\n* Severe concurrent disease.\n* Liver cirrhosis.",{"count":20,"type":21},[24],"The goal of this trial is to determine the efficacy of levofloxacin based sequential treatment regimen or concomitant levofloxacin based regimens as empirical first-line therapy in the Syrian population",[27],[57,58,59,60],"Helicobacter Pylori","levofloxacine","concomitant","sequential","2023-09-27",{"date":63,"type":36},"2023-10-03",{"date":65,"type":21},"2024-01-02",{"date":67,"type":21},"2027-06-30",{"name":42,"class":43},""]